Shares in Ozempic maker Novo Nordisk tumbled after an experimental anti-obesity shot fell short of expectations. The shares fell more than 20% in Copenhagen, closing at their lowest since August 2023.

Eli Lilly, a competitor in the market for GLP-1 weight loss drugs, was up about 5%. Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Novo Nordisk (NVO) stock dropped more than 15% on Friday following an update on its obesity drug that fell short of expectations. Headlines from the company’s press release revealed that Novo ...

Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more effective ...

Novo Nordisk’s shares fell by the most on record after patients using its experimental obesity shot CagriSema lost less weight than predicted in a study, throwing into question the drugmaker’s ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising too much in the cut-throat market for weight-loss drugs. The Danish ...

Novo Nordisk's stock suffered its biggest one-day slide on record after its latest obesity drug trial disappointed investors hoping for another blockbuster weight-loss drug. The Ozempic-maker's ...

(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...

Jefferies analyst Peter Welford maintained a Sell rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK575.00. The company’s shares closed yesterday at DKK743.20.

Bad news for Novo Nordisk (NYSE: NVO) Friday was good news for Eli Lilly (NYSE: LLY) and Viking Therapeutics (NASDAQ: VKTX), its two main rivals in the field of weight loss drugs. This morning ...

COPENHAGEN: Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged on Friday (Dec 20) after it announced disappointing ...